MedTrace Logo

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

NCT06617091 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-13

No results posted yet for this study

Summary

A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa

Conditions

Interventions

DRUG

GRAdHIVNE1 Vaccine

This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.

OTHER

Placebo

This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.

Sponsors & Collaborators

  • Ragon Institute

    collaborator UNKNOWN

  • ReiThera Srl

    collaborator INDUSTRY

  • Mutala Trust

    collaborator UNKNOWN

  • International AIDS Vaccine Initiative

    lead NETWORK

Principal Investigators

  • Tariro Makadzange · Mutala Trust

  • Theodorah Ndzhukule · Desmond Tutu Health Foundation

  • Limakatso Lebina · Africa Health Research Institute (AHRI)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-28
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • South Africa
  • Zimbabwe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06617091 on ClinicalTrials.gov